NFSG
CRSP icon

Newbridge Financial Services Group’s CRISPR Therapeutics CRSP Stock Holding History

Newbridge Financial Services Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.5K Hold
430
– – ﹤0.01% 676
2026
Q1 		$20.5K Buy
430
+30
+8% +$1.58K ﹤0.01% 632
2025
Q4 		$21K Buy
400
+100
+33% +$5.99K ﹤0.01% 632
2025
Q3 		$19.4K Buy
300
+100
+50% +$5.74K ﹤0.01% 754
2025
Q2 		$9.73K Buy
+200
New +$7.74K ﹤0.01% 897
2025
Q1 		– Sell
-29
Closed -$1.14K – 1064
2024
Q4 		$1.14K Sell
29
-171
-86% -$8.07K ﹤0.01% 1009
2024
Q3 		$9.4K Sell
200
-576
-74% -$29.2K ﹤0.01% 437
2024
Q2 		$41.9K Hold
776
– – 0.02% 408
2024
Q1 		$52.9K Sell
776
-300
-28% -$21.5K 0.02% 386
2023
Q4 		$67.4K Buy
1,076
+358
+50% +$19.8K 0.03% 339
2023
Q3 		$32.6K Buy
718
+200
+39% +$10.3K 0.02% 529
2023
Q2 		$29.1K Hold
518
– – 0.01% 590
2023
Q1 		$23.4K Hold
518
– – 0.01% 663
2022
Q4 		$21.1K Hold
518
– – 0.01% 705
2022
Q3 		$34K Buy
518
+2
+0.4% +$145 0.02% 552
2022
Q2 		$31K Sell
516
-337
-40% -$19.8K 0.02% 519
2022
Q1 		$54K Buy
853
+288
+51% +$18.1K 0.03% 461
2021
Q4 		$43K Buy
565
+279
+98% +$24.4K 0.02% 506
2021
Q3 		$32K Buy
286
+51
+22% +$6.41K 0.02% 538
2021
Q2 		$38K Hold
235
– – 0.02% 528
2021
Q1 		$29K Sell
235
-1,150
-83% -$174K 0.02% 589
2020
Q4 		$212K Sell
1,385
-259
-16% -$30.6K 0.17% 131
2020
Q3 		$138K Buy
+1,644
New +$146K 0.14% 155

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Newbridge Financial Services Group's CRSP Position: Q2 2026 in Review

Newbridge Financial Services Group held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 430 shares worth $23.5K. The position accounts for ﹤0.01% of the portfolio, ranked #676.

Newbridge Financial Services Group first reported a position in CRSP in Q3 2020 and has held it in 23 quarters since. The position peaked at $212K in Q4 2020. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Newbridge Financial Services Group held 430 shares of CRISPR Therapeutics worth $23.5K as of Q2 2026.
  • Newbridge Financial Services Group left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q2 2026, its #676 holding.
  • Newbridge Financial Services Group first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Newbridge Financial Services Group's CRISPR Therapeutics position peaked at $212K in Q4 2020.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Newbridge Financial Services Group's 13F filing for Q2 2026, filed 14 Aug 2026.